Aucta Pharmaceuticals Announces Licensing of Vigabatrin for Oral Solution in China
PISCATAWAY, N.J., July 25, 2019 (GLOBE NEWSWIRE) -- Aucta Pharmaceuticals, Inc. (Aucta), a technology based company focusing on the development and commercialization of Branded Specialty Products, today announced that the Company has entered into an exclusive license agreement (“the Agreement”) with Jiangsu Wanbang Biopharmaceuticals Group Co., Ltd., a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma"), to license its China marketing rights for its U.S. FDA approved Vigabatrin for Oral Solution.
Fosun Pharma is a leading healthcare group in China with extensive healthcare business interests worldwide. It is listed on both the Shanghai Stock Exchange and the Hong Kong Stock Exchange.
Aucta’s Vigabatrin for Oral Solution product was approved by U.S. FDA and launched in the U.S. market in July 2018. Vigabatrin for Oral Solution is one of the very few FDA approved effective treatment of infantile spasms (IS) and certain percent of adults with complex partial seizures (CPS) whose seizures remain uncontrolled in spite of having many antiepileptic therapies already available. Vigabatrin for Oral Solution and is not currently approved in China. Aucta is in the process of seeking its import drug license (IDL) with National Medical Products Administration (NMPA) (formerly China Food and Drug Administration or CFDA).
Vigabatrin for Oral Solution will fulfill a significant unmet medical need for pediatric patients with infantile spasms in China who require an NMPA approved medicine to effectively manage their condition. It is estimated there are more than 10,000 new-borns every year in China who have the condition of infantile spasms that would need an effective disease management. Vigabatrin for Oral Solution has the advantage of being body-weight adjustable and ease of dosing for the intended patient population.
Shoufeng Li, Chief Executive Officer of Aucta Pharmaceuticals said: “We are excited to be partnering with Fosun, one of the leading and distinguished pharmaceutical firms in China. China represents a significant market opportunity for our product. We look forward to working closely with Fosun’s talented commercial team to bring this innovative treatment forward and to address the unmet medical need in infantile spasms and seizure treatment.”
Yifang Wu, President & Chief Executive Officer of Fosun Pharma, said: "We are very excited to collaborate with Aucta, one of the emerging specialty pharma companies. The licensed product will bring a lot of strategic synergies with our current CNS business, addressing critical unmet needs in the China market. Aucta’s product is one of the most suitable forms for the targeted patient population. The collaboration with Aucta will contribute to the strategic leading position of Fosun Pharma in this area in China, and also help us to enrich the pipelines for rare disease medical solutions."
Vigabatrin has a black-box warning of potential vision loss. It can cause permanent vision loss in infants, children and adults. Vigabatrin induced vision loss includes progressive and permanent bilateral concentric visual field constriction in 30 percent or more of patients on the therapy that ranges in severity from mild to severe, including tunnel vision to within 10 degrees of visual fixation, and can result in disability. There are also some reports that Vigabatrin can damage the central retina and decrease visual acuity.
The onset is unpredictable and can occur within weeks of starting treatment, or sooner, or at anytime during treatment even after months or years.
About Aucta Pharmaceuticals
Aucta Pharmaceuticals, Inc. is a research and technology based pharmaceutical company focusing on the development and commercialization of niche generic and branded specialty products. The company’s corporate strategy is to focus on proven molecules, and, through innovation, create new therapeutics with lower scientific risk that fulfill unmet medical needs. Aucta’s specialty division has a therapeutic focus in CNS, Dermatology, and Pediatrics.
About Fosun Pharmaceuticals
Fosun Pharmaceuticals (“Fosun Pharma”; stock code: 600196.SH, 02196.HK) is a leading healthcare group in the PRC. Adhering to the mission of improving human health, Fosun Pharma’s business covers all key sectors of the healthcare industry chain, including pharmaceutical manufacturing and R&D, healthcare services, medical devices and medical diagnosis, as well as pharmaceutical distribution and retail, with pharmaceutical manufacturing and R&D as the core, and healthcare services as the development focus.
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements associated with the expected ability of Aucta to undertake certain activities and accomplish certain goals and objectives. These statements include but are not limited to statements regarding Aucta’s business strategy, Aucta’s plans to develop and commercialize its product candidates, the safety and efficacy of Aucta’s product candidates, Aucta’s plans and expected timing with respect to regulatory filings and approvals, and the size and growth potential of the markets for Aucta’s product candidates. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "intends," "will," "goal," "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Aucta’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. These and other risks concerning Aucta’s business, development programs, and financial condition are described in additional detail in Aucta’s filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Aucta undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
Upcoming Life Sciences Events
- August 2020
- ChinaBio® Partnering Forum 2020 Digital
- Biotechgate Digital Partnering Event
- September 2020
- Basel: Pharma-Biotech Product & Company Valuation
Latest company news
Innovent and Lilly Release Clinical Trial Results of Sintilimab in Combination with ALIMTA(R) (Pemetrexed) and Platinum Chemotherapy as First-Line Treatment for Nonsquamous NSCLC in an Oral Presentation at IASLC WCLC 2020 Virtual Presidential Symposi
Innovent and Lilly Release Clinical Trial Results of Sintilimab in Combination with ALIMTA® (Pemetrexed) and Platinum Chemotherapy as First-Line Treatment for Nonsquamous NSCLC in an Oral Presentation at IASLC WCLC 2020 Virtual Presidential Symposium